{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:23:22Z","timestamp":1782127402351,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.dmpk.2022.100480","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T13:18:17Z","timestamp":1666099097000},"page":"100480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1631-3178","authenticated-orcid":false,"given":"Nontaya","family":"Nakkam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-2371","authenticated-orcid":false,"given":"Niwat","family":"Saksit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinya","family":"Konyoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warayuwadee","family":"Amornpinyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usanee","family":"Khunarkornsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danklai","family":"Purimart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oranuch","family":"Pattanacheewapull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaporn","family":"Naewla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pansakon","family":"Wattanachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanyarat","family":"Khaeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pansu","family":"Chumworathayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6722-8796","authenticated-orcid":false,"given":"Wichittra","family":"Tassaneeyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dmpk.2022.100480_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(14)71011-4","article-title":"The expanding role of co-trimoxazole in developing countries","volume":"15","author":"Church","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"10.1016\/j.dmpk.2022.100480_bib2","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100480_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1071","article-title":"The medication risk of stevens-johnson syndrome and toxic epidermal necrolysis in asians: the major drug causality and comparison with the US FDA label","volume":"105","author":"Wang","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100480_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tox.2004.12.022","article-title":"Clinical heterogeneity of drug hypersensitivity","volume":"209","author":"Roujeau","year":"2005","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100480_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100480_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dmpk.2022.100480_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FPC.0000000000000153","article-title":"Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions","volume":"25","author":"Kongpan","year":"2015","journal-title":"Pharmacogenetics Genom"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100480_bib8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/cpt.1915","article-title":"Genetic association of Co-Trimoxazole-Induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes","volume":"108","author":"Sukasem","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100480_bib9","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians","volume":"147","author":"Wang","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100480_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/clpt.1991.3","article-title":"Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions","volume":"49","author":"Rieder","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2022.100480_bib11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1755-8794-5-32","article-title":"Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV\/AIDS patients","volume":"5","author":"Wang","year":"2012","journal-title":"BMC Med Genom"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100480_bib12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0090-9556(25)08967-6","article-title":"Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity","volume":"19","author":"Cribb","year":"1991","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100480_bib13","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/0006-2952(93)90280-A","article-title":"Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism","volume":"45","author":"Cribb","year":"1993","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100480_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00002030-199403000-00006","article-title":"Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients","volume":"8","author":"Carr","year":"1994","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100480_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.1994.tb04401.x","article-title":"N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients","volume":"38","author":"Delomenie","year":"1994","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100480_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00008571-199712000-00011","article-title":"Glutathione S-transferase (GSTM1) null genotype and sulphonamide intolerance in acquired immunodeficiency syndrome","volume":"7","author":"Delomenie","year":"1997","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100480_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1008664707825","article-title":"Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants","volume":"20","author":"Zielinska","year":"1998","journal-title":"Pharm World Sci"},{"issue":"10","key":"10.1016\/j.dmpk.2022.100480_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00403-003-0446-z","article-title":"Glutathione S-transferase polymorphisms in patients with drug eruption","volume":"295","author":"Ates","year":"2004","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100480_bib19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0006-2952(91)90334-2","article-title":"Glutathione transferase mu deficiency is not a marker for predisposition to sulphonamide toxicity","volume":"42","author":"Riley","year":"1991","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"10.1016\/j.dmpk.2022.100480_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00008571-200011000-00005","article-title":"Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity","volume":"10","author":"Pirmohamed","year":"2000","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100480_bib21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bcp.15022","article-title":"Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine","volume":"88","author":"Nakkam","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100480_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmpk.2022.100480_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0304-3835(96)04832-X","article-title":"A\u00a0multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies","volume":"107","author":"Abdel-Rahman","year":"1996","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.dmpk.2022.100480_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160570","article-title":"Combined GSTM1-null, GSTT1-active, GSTA1 low-activity and GSTP1-variant genotype is associated with increased risk of clear cell renal cell carcinoma","volume":"11","author":"Coric","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100480_bib25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg777","article-title":"Patterns of linkage disequilibrium in the human genome","volume":"3","author":"Ardlie","year":"2002","journal-title":"Nat Rev Genet"},{"issue":"7","key":"10.1016\/j.dmpk.2022.100480_bib26","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/QAD.0000000000000206","article-title":"HLA-B\u221735: 05 is a protective allele with a unique structure among HIV-1 CRF01_AE-infected Thais, in whom the B\u221757 frequency is low","volume":"28","author":"Mori","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.dmpk.2022.100480_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fgene.2018.00277","article-title":"HLA pharmacogenetic markers of drug hypersensitivity in a Thai population","volume":"9","author":"Nakkam","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.dmpk.2022.100480_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fphar.2020.00078","article-title":"Genetic diversity of HLA class I and class II alleles in Thai populations: contribution to genotype-guided therapeutics","volume":"11","author":"Satapornpong","year":"2020","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100480_bib29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0952-7915(99)80078-8","article-title":"Host genetic influences on HIV-1 pathogenesis","volume":"11","author":"Michael","year":"1999","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.dmpk.2022.100480_bib30","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1086\/315854","article-title":"HLA class I alleles associated with susceptibility or resistance to human immunodeficiency virus type 1 infection among a population in Chaco Province, Argentina","volume":"182","author":"de Sorrentino","year":"2000","journal-title":"J\u00a0Infect Dis"},{"issue":"6982","key":"10.1016\/j.dmpk.2022.100480_bib31","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100480_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenetics Genom"},{"issue":"8","key":"10.1016\/j.dmpk.2022.100480_bib33","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2019.12.025","article-title":"Association of HLA-A\u221711:01 with sulfonamide-related severe cutaneous adverse reactions in Japanese patients","volume":"140","author":"Nakamura","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.dmpk.2022.100480_bib34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/mol.62.3.628","article-title":"Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation","volume":"62","author":"Naisbitt","year":"2002","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2022.100480_bib35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-199902000-00007","article-title":"The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation","volume":"9","author":"Gill","year":"1999","journal-title":"Pharmacogenetics"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100480_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156000","article-title":"Genome-wide association study in immunocompetent patients with delayed hypersensitivity to sulfonamide antimicrobials","volume":"11","author":"Reinhart","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.dmpk.2022.100480_bib37","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1158\/0008-5472.CAN-07-6724","article-title":"Glutathione s-transferase p1: gene sequence variation and functional genomic studies","volume":"68","author":"Moyer","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100480_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/carcin\/18.4.641","article-title":"Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer","volume":"18","author":"Harries","year":"1997","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100480_bib39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00130832-200208000-00003","article-title":"Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept","volume":"2","author":"Pichler","year":"2002","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.dmpk.2022.100480_bib40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/WOX.0b013e3181778282","article-title":"The p-i concept: pharmacological interaction of drugs with immune receptors","volume":"1","author":"Pichler","year":"2008","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.dmpk.2022.100480_bib41","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B\u22171502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436722000374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436722000374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:57:02Z","timestamp":1761163022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436722000374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":41,"alternative-id":["S1347436722000374"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2022.100480","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2022.100480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100480"}}